Cargando…

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels

BACKGROUND AND AIMS: Regorafenib has demonstrated its survival benefit for unresectable hepatocellular carcinoma (uHCC) patients in a phase III clinical trial. We aimed to assess the efficacy and tolerability of regorafenib and the predictors of treatment outcomes in Taiwanese patients. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Po‐Yao, Cheng, Tzu‐Sheng, Chuang, Shih‐Chang, Chang, Wen‐Tsan, Liang, Po‐Cheng, Hsu, Cheng‐Ting, Wei, Yu‐Ju, Jang, Tyng‐Yuan, Yeh, Ming‐Lun, Huang, Ching‐I, Lin, Yi‐Hung, Wang, Chih‐Wen, Hsieh, Ming‐Yen, Hou, Nai‐Jen, Hsieh, Meng‐Hsuan, Tsai, Yi‐Shan, Ko, Yu‐Min, Lin, Ching‐Chih, Chen, Kuan‐Yu, Dai, Chia‐Yen, Lin, Zu‐Yau, Chen, Shinn‐Cherng, Huang, Jee‐Fu, Chuang, Wan‐Long, Huang, Chung‐Feng, Yu, Ming‐Lung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704159/ https://www.ncbi.nlm.nih.gov/pubmed/34786871 http://dx.doi.org/10.1002/cam4.4430

Ejemplares similares

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021)

Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C
por: Yeh, Ming-Lun, et al.
Publicado: (2018)

Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort
por: Huang, Chung-Feng, et al.
Publicado: (2023)

Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan
por: Tsai, Pei-Chien, et al.
Publicado: (2021)

Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication
por: Lu, Ming-Ying, et al.
Publicado: (2022)

Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan
por: Lu, Ming-Ying, et al.
Publicado: (2021)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
por: Hsu, Po-Yao, et al.
Publicado: (2021)

Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C: A Nationwide Survey in Taiwan
por: Yu, Ming-Lung, et al.
Publicado: (2015)

The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C
por: Lee, Jia-Jung, et al.
Publicado: (2020)

Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients
por: Huang, Jee-Fu, et al.
Publicado: (2015)

Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2019)

A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic
por: Huang, Ching-I, et al.
Publicado: (2023)

Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Itemization difference of patient-reported outcome in patients with chronic liver disease
por: Lin, Ming-Chieh, et al.
Publicado: (2022)

Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison
por: Chen, Chun-Ting, et al.
Publicado: (2022)

Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVR
por: Hsu, Po-Yao, et al.
Publicado: (2022)

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
por: Jang, Tyng-Yuan, et al.
Publicado: (2021)

Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease
por: Huang, Jee-Fu, et al.
Publicado: (2023)

Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)
por: Huang, Jee-Fu, et al.
Publicado: (2021)

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study
por: Yu, Ming-Lung, et al.
Publicado: (2005)

Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2023)

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database
por: Tsai, Pei-Chien, et al.
Publicado: (2017)

Using Anti-Malondialdehyde Modified Peptide Autoantibodies to Import Machine Learning for Predicting Coronary Artery Stenosis in Taiwanese Patients with Coronary Artery Disease
por: Hsu, Yu-Cheng, et al.
Publicado: (2021)

Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus
por: Chien, Ming‐Nan, et al.
Publicado: (2016)

Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Viral Interference Between Dengue Virus and Hepatitis C Virus Infections
por: Liang, Po-Cheng, et al.
Publicado: (2020)

Sex-specific genetic variants associated with adult-onset inguinal hernia in a Taiwanese population
por: Yen, Hsin-Chien, et al.
Publicado: (2023)

Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes
por: Huang, Ching-I, et al.
Publicado: (2018)

Association of hyperuricemia with disease severity in chronic hepatitis C patients
por: Jang, Tyng-Yuan, et al.
Publicado: (2018)

Blood biomarkers of various dietary patterns correlated with metabolic indicators in Taiwanese type 2 diabetes
por: Huang, Meng-Chuan, et al.
Publicado: (2019)

Infection control measures of a Taiwanese hospital to confront the COVID‐19 pandemic
por: Chang, Ya‐Ting, et al.
Publicado: (2020)

Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients
por: Jang, Tyng-Yuan, et al.
Publicado: (2017)

Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients
por: Huang, Jee-Fu, et al.
Publicado: (2017)

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients
por: Batsaikhan, Batbold, et al.
Publicado: (2022)

The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma
por: Yeh, Ming-Lun, et al.
Publicado: (2017)

Virological Predictors of Response to Retreatment in Hepatitis C Genotype 2 Infected Patients
por: Huang, Chung-Feng, et al.
Publicado: (2013)

Case Report: Vaccine-Induced Immune Thrombotic Thrombocytopenia in a Pancreatic Cancer Patient After Vaccination With Messenger RNA−1273
por: Su, Po-Hsu, et al.
Publicado: (2021)

Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C
por: Tsai, Yi-Shan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4a25n95rp9t0daduslmr87g3j6